{"protocolSection":{"identificationModule":{"nctId":"NCT00938314","orgStudyIdInfo":{"id":"NTx®-265-CP-202-IS"},"organization":{"fullName":"Stem Cell Therapeutics Corp.","class":"INDUSTRY"},"briefTitle":"Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients","officialTitle":"A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled, Multicenter, Dose Escalation Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS-LED)","acronym":"REGENESIS-LED"},"statusModule":{"statusVerifiedDate":"2011-11","overallStatus":"TERMINATED","whyStopped":"Slow Enrollment","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-08"},"primaryCompletionDateStruct":{"date":"2010-04","type":"ACTUAL"},"completionDateStruct":{"date":"2010-04","type":"ACTUAL"},"studyFirstSubmitDate":"2009-07-09","studyFirstSubmitQcDate":"2009-07-10","studyFirstPostDateStruct":{"date":"2009-07-13","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-09-01","resultsFirstSubmitQcDate":"2011-11-04","resultsFirstPostDateStruct":{"date":"2011-11-09","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-11-24","lastUpdatePostDateStruct":{"date":"2011-11-29","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Stem Cell Therapeutics Corp.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is:\n\n* To assess the neurological outcome in acute ischemic stroke patients treated with NTx®-265, when compared with patients given a placebo control.\n* To assess the safety and tolerability of NTx®-265 when given to acute ischemic stroke patients."},"conditionsModule":{"conditions":["Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":96,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"NTx®-265 Low Dose","type":"EXPERIMENTAL","description":"hCG 385 µg (10,000 international unit \\[IU\\]), subcutaneously (SC), on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, intravenously (IV), on Day 7, 8, and 9 of study participation","interventionNames":["Drug: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)"]},{"label":"NTx®-265 Medium Dose","type":"EXPERIMENTAL","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation","interventionNames":["Drug: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)"]},{"label":"NTx®-265 High Dose","type":"EXPERIMENTAL","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation","interventionNames":["Drug: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)"]},{"label":"Saline Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Saline Placebo"]}],"interventions":[{"type":"DRUG","name":"human chorionic gonadotropin (hCG), then epoetin alfa (EPO)","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation","armGroupLabels":["NTx®-265 Low Dose"],"otherNames":["Ovidrel","Ovitrelle","Epogen","Eprex"]},{"type":"DRUG","name":"human chorionic gonadotropin (hCG), then epoetin alfa (EPO)","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation","armGroupLabels":["NTx®-265 Medium Dose"],"otherNames":["Ovidrel","Ovitrelle","Epogen","Eprex"]},{"type":"DRUG","name":"human chorionic gonadotropin (hCG), then epoetin alfa (EPO)","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation","armGroupLabels":["NTx®-265 High Dose"],"otherNames":["Ovidrel","Ovitrelle","Epogen","Eprex"]},{"type":"DRUG","name":"Saline Placebo","description":"Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation","armGroupLabels":["Saline Placebo"],"otherNames":["Sodium Chloride 0.9%"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"National Institutes of Health Stroke Scale (NIHSS) Change From Baseline at Day 90","description":"The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead).","timeFrame":"Baseline and Day 90"}],"secondaryOutcomes":[{"measure":"NIHSS Response >=4 at Day 90","description":"The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead). NIHSS Response \\>=4 is defined as a \\>=4 change from baseline at Day 90.","timeFrame":"Baseline and Day 90"},{"measure":"NIHSS Change From Baseline at Day 30","description":"The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead).","timeFrame":"Baseline and Day 30"},{"measure":"Modified Rankin Scale (mRS) Response <=2 at Day 90","description":"The mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0 (perfect health without symptoms) to 6 (dead). mRS response \\<=2 is defined as the mRS score \\<=2 at Day 90.","timeFrame":"Day 90"},{"measure":"Barthel Index at Day 90","description":"The Barthel Index measures 10 activities of daily living and mobility. A score of 100 = is best (able to live at home with a degree of independence), 0 is worst.","timeFrame":"Day 90"},{"measure":"Action Research Arm Test (ARAT) Change From Baseline at Day 90","description":"The ARAT assesses recovery of arm function following stroke through a series of subtests judging ability to grasp, grip, pinch, or move the arm; scores are on a scale; The total maximum (best) score is 57 and the total minimum (worst) score is 0.","timeFrame":"Baseline and Day 90"},{"measure":"Gait Velocity Test Change From Baseline at Day 90","description":"The Gait Velocity Test assesses ability to walk as measured by the time (seconds) it takes a patient to walk 10 meters.","timeFrame":"Baseline and Day 90"},{"measure":"Boston Naming Test (BNT) Change From Baseline at Day 90","description":"The BNT assesses impairment of language ability by asking patients to identify 20 different pictures each time the test is taken. A score of 20 is best, 0 is worst.","timeFrame":"Baseline and Day 90"},{"measure":"Line Cancellation Test Change From Baseline at Day 90","description":"The Line Cancellation Test detects the loss of awareness of one side of the body. A score of 0.00 (no units) is normal (patient favors neither right nor left side). A score of +1.00 indicates severe unawareness of the left side. A score of -1.00 indicates severe unawareness of the right side.","timeFrame":"Baseline and Day 90"},{"measure":"Trails A Test Change From Baseline at Day 90","description":"The Trails A test measures visual scanning, numeric sequencing, and visual-motor coordination; the test score is the time (seconds) required to connect 25 numbers (e.g., 1, 2, 3, 4...)","timeFrame":"Baseline and Day 90"},{"measure":"Trails B Test Change From Baseline at Day 90","description":"The Trails B test measures visual scanning, numeric sequencing, and visual-motor coordination; the test score is the time (seconds) required to connect 25 alpha numeric circles (e.g., 1, A, 2, B, 3, C, 4, D)","timeFrame":"Baseline and Day 90"},{"measure":"Geriatric Depression Scale at Day 90","description":"The Geriatric Depression Scale is commonly used to assess depression in stroke patients of any age by asking 15 yes/no questions, and then scored. A score of 0 - 5 is normal, whereas a score of 6 -15 suggests depression.","timeFrame":"Day 90"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18-85\n* NIHSS score 8-20\n* Stroke is ischemic in origin, supratentorial, and radiologically confirmed\n* Patient is 24-48 hours from time of stroke onset when the first dose of NTx®-265 therapy is administered\n* Reasonable expectation of availability to receive the full 9 day NTx®- 265 therapy and subsequent follow-up visits\n* Reasonable expectation that patient will receive standard post-stroke physical, occupational, speech, and cognitive therapy as indicated\n* Female patient is either not of childbearing potential or agrees to use two of the effective separate non-hormonal forms of contraception throughout the study\n\nExclusion Criteria:\n\n* Patients presenting with lacunar, hemorrhagic and/or brain stem stroke\n* Patients who have received tissue plasminogen activator (tPA)following the index stroke\n* Patients classified as comatose\n* Women who have tested positive for pregnancy, or are breast-feeding, or are not using a birth control\n* Serum hemoglobin \\> 16 grams(g)/deciliter (dL)(males) or \\> 14 g/dL (females); or platelet count \\> 400,000/cubic millimeters(mm3)\n* Advanced liver, kidney, cardiac, or pulmonary disease\n* Elevated serum bilirubin,alkaline phosphatase, aspartate aminotransferase (AST) or alanine transaminase (ALT),creatinine, or prostate-specific antigen (PSA) levels\n* Patients with a known history of hypercoagulability\n* Expected survival \\< 1 year\n* Allergy or other contraindication to hCG or EPO\n* A known diagnosis of cancer in the previous 5 years\n* Uncontrolled hypertension\n* Use of either hCG or epoetin alfa within the previous 90 days\n* Any condition known to elevate hCG\n* Patients with a pre-stroke/pre-morbid modified Rankin Score (mRS)≥ 2\n* Any patients not living independently\n* Any other medical condition or degree of stroke such that, in the investigator's opinion, the patient should not be included in the trial\n* With the exception of the qualifying stroke, any other stroke within the previous 3 months\n* Patients who cannot take anti-platelet or anti-coagulant therapy\n* Pre-existing and active major psychiatric or other chronic neurological disease\n* Alcohol abuse or have a history of substance abuse or dependency within 12 months prior to the study\n* Currently participating in another investigational study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Steven C Cramer, MD","affiliation":"Department of Neurology, University of California, Irvine Medical Center","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Michael D Hill, MD","affiliation":"Department of Clinical Neurosciences, University of Calgary","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"University of California, Irvine Medical Center","city":"Orange","state":"California","zip":"92868","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"Foothills Medical Center , University of Calgary","city":"Calgary","state":"Alberta","zip":"T2N 2T9","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"Queen Elizabeth II Health Sciences Center","city":"Halifax","state":"Nova Scotia","zip":"B3H 3A7","country":"Canada","geoPoint":{"lat":44.64533,"lon":-63.57239}},{"facility":"Sunnybrook Health Sciences Centre","city":"Toronto","state":"Ontario","zip":"M4N 3M5","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"Montreal Neurological Institute","city":"Montreal","state":"Quebec","zip":"H3A 2B4","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Lalitha Super Specialty Hospitals Pvt.Ltd","city":"Guntur","state":"Andhra Pradesh","zip":"522001","country":"India","geoPoint":{"lat":16.29974,"lon":80.45729}},{"facility":"Care Hospital","city":"Hyderabad","state":"Andhra Pradesh","zip":"500001","country":"India","geoPoint":{"lat":17.38405,"lon":78.45636}},{"facility":"Krishna Institute of Medical Sciences","city":"Hyderabad","state":"Andhra Pradesh","zip":"500003","country":"India","geoPoint":{"lat":17.38405,"lon":78.45636}},{"facility":"St.Theresa's General Hospital","city":"Hyderabad","state":"Andhra Pradesh","zip":"500018","country":"India","geoPoint":{"lat":17.38405,"lon":78.45636}},{"facility":"Apollo Hospitals","city":"Hyderabad","state":"Andhra Pradesh","zip":"500023","country":"India","geoPoint":{"lat":17.38405,"lon":78.45636}},{"facility":"Owaisi Hospital and Research Centre","city":"Hyderabad","state":"Andhra Pradesh","zip":"500059","country":"India","geoPoint":{"lat":17.38405,"lon":78.45636}},{"facility":"Mediciti Hospital","city":"Hyderabad","state":"Andhra Pradesh","zip":"500063","country":"India","geoPoint":{"lat":17.38405,"lon":78.45636}},{"facility":"Kamineni Hospital","city":"Hyderabad","state":"Andhra Pradesh","zip":"500068","country":"India","geoPoint":{"lat":17.38405,"lon":78.45636}},{"facility":"DBR & SK Super Speciality Hospital","city":"Tirupati","state":"Andhra Pradesh","zip":"517501","country":"India","geoPoint":{"lat":13.63551,"lon":79.41989}},{"facility":"Latha Superspecialities Hospital","city":"Vijayawada","state":"Andhra Pradesh","zip":"520002","country":"India","geoPoint":{"lat":16.50745,"lon":80.6466}},{"facility":"Suraksha Neuro Centre","city":"Vijayawada","state":"Andhra Pradesh","zip":"520002","country":"India","geoPoint":{"lat":16.50745,"lon":80.6466}},{"facility":"Max Super Speciality Hospital","city":"New Delhi","state":"Delhi","zip":"110017","country":"India","geoPoint":{"lat":28.63576,"lon":77.22445}},{"facility":"M S Ramaiah Memorial Hospital","city":"Bangalore","state":"Karnataka","zip":"560054","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"J.S.S Medical College & Hospital","city":"Bangalore","state":"Karnataka","zip":"570004","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"Ananthapuri Hospitals and Research Institute","city":"Thiruvananthapuram","state":"Kerala","zip":"695024","country":"India","geoPoint":{"lat":8.4855,"lon":76.94924}},{"facility":"Christian Medical College and Hospital","city":"Ludhiana","state":"Punjab","zip":"141008","country":"India","geoPoint":{"lat":30.91204,"lon":75.85379}},{"facility":"Vijaya Health Center","city":"Chennai","state":"Tamilnadu","zip":"600026","country":"India","geoPoint":{"lat":13.08784,"lon":80.27847}},{"facility":"Christian Medical College Hospital","city":"Vellore","state":"Tamilnadu","zip":"632004","country":"India","geoPoint":{"lat":12.9184,"lon":79.13255}}]},"referencesModule":{"references":[{"pmid":"24588854","type":"DERIVED","citation":"Cramer SC, Hill MD; REGENESIS-LED Investigators. Human choriogonadotropin and epoetin alfa in acute ischemic stroke patients (REGENESIS-LED trial). Int J Stroke. 2014 Apr;9(3):321-7. doi: 10.1111/ijs.12260. Epub 2014 Mar 3."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"NTx®-265 Low Dose","description":"human chorionic gonadotropin (hCG) 385 µg (10,000 international unit \\[IU\\]), subcutaneously (SC), on Day 1, 3 and 5 of study participation, then epoetin alfa (EPO) 4,000 IU, intravenously (IV), on Day 7, 8, and 9 of study participation"},{"id":"FG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"FG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"FG003","title":"Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation"}],"periods":[{"title":"Cohort 1","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"8"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}]}]},{"title":"Cohort 2","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"8"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}]}]},{"title":"Cohort 3","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"24"},{"groupId":"FG003","numSubjects":"8"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"20"},{"groupId":"FG003","numSubjects":"7"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"NTx®-265 Low Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"BG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"BG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"BG003","title":"Saline Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation"},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"96"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"67"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"29"}]}]}]},{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57.42","spread":"10.49"},{"groupId":"BG001","value":"58.58","spread":"13.32"},{"groupId":"BG002","value":"54.83","spread":"12.98"},{"groupId":"BG003","value":"61.67","spread":"12.38"},{"groupId":"BG004","value":"58.13","spread":"12.39"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"65"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"31"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Canada","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"}]}]},{"title":"India","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"94"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"National Institutes of Health Stroke Scale (NIHSS) Change From Baseline at Day 90","description":"The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead).","populationDescription":"The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on a scale","timeFrame":"Baseline and Day 90","groups":[{"id":"OG000","title":"NTx®-265 Low Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG003","title":"Saline Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.79","spread":"4.22"},{"groupId":"OG001","value":"6.50","spread":"4.53"},{"groupId":"OG002","value":"6.08","spread":"3.30"},{"groupId":"OG003","value":"7.17","spread":"4.24"}]}]}]},{"type":"SECONDARY","title":"NIHSS Response >=4 at Day 90","description":"The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead). NIHSS Response \\>=4 is defined as a \\>=4 change from baseline at Day 90.","populationDescription":"The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline and Day 90","groups":[{"id":"OG000","title":"NTx®-265 Low Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG003","title":"Saline Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"}]}],"classes":[{"title":"No Response (<4)","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"}]}]},{"title":"Response (>=4)","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"19"}]}]}]},{"type":"SECONDARY","title":"NIHSS Change From Baseline at Day 30","description":"The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead).","populationDescription":"The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on a scale","timeFrame":"Baseline and Day 30","groups":[{"id":"OG000","title":"NTx®-265 Low Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG003","title":"Saline Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.67","spread":"4.53"},{"groupId":"OG001","value":"4.29","spread":"3.37"},{"groupId":"OG002","value":"5.00","spread":"2.98"},{"groupId":"OG003","value":"5.33","spread":"3.33"}]}]}]},{"type":"SECONDARY","title":"Modified Rankin Scale (mRS) Response <=2 at Day 90","description":"The mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0 (perfect health without symptoms) to 6 (dead). mRS response \\<=2 is defined as the mRS score \\<=2 at Day 90.","populationDescription":"The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 90","groups":[{"id":"OG000","title":"NTx®-265 Low Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG003","title":"Saline Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"}]}],"classes":[{"title":"response (mRS <=2)","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"18"}]}]},{"title":"No response (mRS > 2)","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"6"}]}]}]},{"type":"SECONDARY","title":"Barthel Index at Day 90","description":"The Barthel Index measures 10 activities of daily living and mobility. A score of 100 = is best (able to live at home with a degree of independence), 0 is worst.","populationDescription":"The analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Day 90","groups":[{"id":"OG000","title":"NTx®-265 Low Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG003","title":"Saline Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.18","spread":"29.62"},{"groupId":"OG001","value":"80.17","spread":"22.04"},{"groupId":"OG002","value":"85.25","spread":"20.28"},{"groupId":"OG003","value":"90.89","spread":"12.69"}]}]}]},{"type":"SECONDARY","title":"Action Research Arm Test (ARAT) Change From Baseline at Day 90","description":"The ARAT assesses recovery of arm function following stroke through a series of subtests judging ability to grasp, grip, pinch, or move the arm; scores are on a scale; The total maximum (best) score is 57 and the total minimum (worst) score is 0.","populationDescription":"Not all patients enrolled in the group completed this outcome measure.\n\nThe analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on a scale","timeFrame":"Baseline and Day 90","groups":[{"id":"OG000","title":"NTx®-265 Low Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG003","title":"Saline Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.67","spread":"13.37"},{"groupId":"OG001","value":"33.50","spread":"26.12"},{"groupId":"OG002","value":"30.33","spread":"16.80"},{"groupId":"OG003","value":"23.75","spread":"20.27"}]}]}]},{"type":"SECONDARY","title":"Gait Velocity Test Change From Baseline at Day 90","description":"The Gait Velocity Test assesses ability to walk as measured by the time (seconds) it takes a patient to walk 10 meters.","populationDescription":"Not all patients enrolled in the group completed this outcome measure.\n\nThe analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"seconds","timeFrame":"Baseline and Day 90","groups":[{"id":"OG000","title":"NTx®-265 Low Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG003","title":"Saline Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.75","spread":"41.60"},{"groupId":"OG001","value":"-50.33","spread":"48.95"},{"groupId":"OG002","value":"-6.40","spread":"7.37"},{"groupId":"OG003","value":"-53.80","spread":"54.15"}]}]}]},{"type":"SECONDARY","title":"Boston Naming Test (BNT) Change From Baseline at Day 90","description":"The BNT assesses impairment of language ability by asking patients to identify 20 different pictures each time the test is taken. A score of 20 is best, 0 is worst.","populationDescription":"Not all patients enrolled in the group completed this outcome measure.\n\nThe analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline and Day 90","groups":[{"id":"OG000","title":"NTx®-265 Low Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG003","title":"Saline Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.93","spread":"3.10"},{"groupId":"OG001","value":"4.17","spread":"4.11"},{"groupId":"OG002","value":"0.20","spread":"2.74"},{"groupId":"OG003","value":"3.69","spread":"3.82"}]}]}]},{"type":"SECONDARY","title":"Line Cancellation Test Change From Baseline at Day 90","description":"The Line Cancellation Test detects the loss of awareness of one side of the body. A score of 0.00 (no units) is normal (patient favors neither right nor left side). A score of +1.00 indicates severe unawareness of the left side. A score of -1.00 indicates severe unawareness of the right side.","populationDescription":"Not all patients enrolled in the group completed this outcome measure.\n\nThe analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on a scale","timeFrame":"Baseline and Day 90","groups":[{"id":"OG000","title":"NTx®-265 Low Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG003","title":"Saline Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.03"},{"groupId":"OG001","value":"-0.07","spread":"0.11"},{"groupId":"OG002","value":"-0.04","spread":"0.10"},{"groupId":"OG003","value":"-0.00","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Trails A Test Change From Baseline at Day 90","description":"The Trails A test measures visual scanning, numeric sequencing, and visual-motor coordination; the test score is the time (seconds) required to connect 25 numbers (e.g., 1, 2, 3, 4...)","populationDescription":"Not all patients enrolled in the group completed this outcome measure.\n\nThe analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"seconds","timeFrame":"Baseline and Day 90","groups":[{"id":"OG000","title":"NTx®-265 Low Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG003","title":"Saline Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.33","spread":"22.20"},{"groupId":"OG001","value":"-21.89","spread":"22.10"},{"groupId":"OG002","value":"-13.29","spread":"21.91"},{"groupId":"OG003","value":"-23.44","spread":"25.53"}]}]}]},{"type":"SECONDARY","title":"Trails B Test Change From Baseline at Day 90","description":"The Trails B test measures visual scanning, numeric sequencing, and visual-motor coordination; the test score is the time (seconds) required to connect 25 alpha numeric circles (e.g., 1, A, 2, B, 3, C, 4, D)","populationDescription":"Not all patients enrolled in the group completed this outcome measure.\n\nThe analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"seconds","timeFrame":"Baseline and Day 90","groups":[{"id":"OG000","title":"NTx®-265 Low Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG003","title":"Saline Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.33","spread":"51.60"},{"groupId":"OG001","value":"-41.33","spread":"62.89"},{"groupId":"OG002","value":"-55.14","spread":"59.92"},{"groupId":"OG003","value":"-22.78","spread":"71.22"}]}]}]},{"type":"SECONDARY","title":"Geriatric Depression Scale at Day 90","description":"The Geriatric Depression Scale is commonly used to assess depression in stroke patients of any age by asking 15 yes/no questions, and then scored. A score of 0 - 5 is normal, whereas a score of 6 -15 suggests depression.","populationDescription":"Not all patients enrolled in the group completed this outcome measure.\n\nThe analysis was conducted using a modified Intent-to-Treat population, defined as all randomized patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"scores on a scale","timeFrame":"Day 90","groups":[{"id":"OG000","title":"NTx®-265 Low Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation"},{"id":"OG003","title":"Saline Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.25","spread":"4.24"},{"groupId":"OG001","value":"3.88","spread":"3.08"},{"groupId":"OG002","value":"3.56","spread":"2.77"},{"groupId":"OG003","value":"4.74","spread":"3.90"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events were captured from the time of first dose to Day 30. Serious adverse events were captured from the time of first dose to Day 90.","eventGroups":[{"id":"EG000","title":"NTx®-265 Low Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation","seriousNumAffected":2,"seriousNumAtRisk":24,"otherNumAffected":9,"otherNumAtRisk":24},{"id":"EG001","title":"NTx®-265 Medium Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation","seriousNumAffected":4,"seriousNumAtRisk":24,"otherNumAffected":19,"otherNumAtRisk":24},{"id":"EG002","title":"NTx®-265 High Dose","description":"hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation","seriousNumAffected":3,"seriousNumAtRisk":24,"otherNumAffected":2,"otherNumAtRisk":24},{"id":"EG003","title":"Saline Placebo","description":"saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation","seriousNumAffected":2,"seriousNumAtRisk":24,"otherNumAffected":10,"otherNumAtRisk":24}],"seriousEvents":[{"term":"Cardiac Arrest","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Cardio-Respiratory Arrest","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Cerebral Vascular Accident","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Gastrointestinal Hemorrhage","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Hemorrhagic Transformation Stroke","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Ischemic Stroke","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Sudden Cardiac Death","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Ventricular Fibrillation","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":24}]}],"otherEvents":[{"term":"Depression","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":24}]},{"term":"Musculoskeletal Pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":24}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Pyrexia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":24},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":24}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":24}]},{"term":"Vomitting","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"The trial was terminated after 96 of a planned 128 patients were enrolled, thus limiting opportunities to demonstrate a clear statistical benefit of active therapy compared to placebo."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Scientific Officer","organization":"Stem Cell Therapeutics Corp.","email":"adavidoff@stemcellthera.com","phone":"403.245.5495","phoneExt":"226"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068817","term":"Epoetin Alfa"},{"id":"D000006063","term":"Chorionic Gonadotropin"}],"ancestors":[{"id":"D000006397","term":"Hematinics"},{"id":"D000012102","term":"Reproductive Control Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M314","name":"Epoetin Alfa","asFound":"Postmenopausal","relevance":"HIGH"},{"id":"M8858","name":"Chorionic Gonadotropin","asFound":"Amniotic","relevance":"HIGH"},{"id":"M9175","name":"Hematinics","relevance":"LOW"}],"browseBranches":[{"abbrev":"Hemat","name":"Hematinics"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Repr","name":"Reproductive Control Agents"}]}},"hasResults":true}